Avio expands Quantiplus across SEA

Diagnostics is the thing here — not just another vague “healthtech expansion” headline. Avio Smart Market Stack and Huwel Lifesciences said on April 27 that they’ve brought in a Singapore-based commercialization partner to push Huwel’s Quantiplus platform across Southeast Asia. The immediate plan covers six markets: Singapore, Indonesia, Malaysia, Thailand, Vietnam, and the Philippines. Basically, this is a go-to-market move for an Indian diagnostics product that now wants regional scale. (manufacturing.economictimes.indiatimes.com) ### What is Quantiplus, exactly? Quantiplus is Huwel’s molecular diagnostics platform. That means lab-style testing built around detecting disease at the molecular level, with an initial pitch around affordability, scalability, and use in institutional and public-health settings. In this expansion, Quantiplus is the lead product — the wedge they’re using to enter new markets before adding other testing tools later. (manufacturing.economictimes.indiatimes.com) ### Why does Singapore matter here? Singapore looks less like the end market and more like the launchpad. The companies did not name the partner in the coverage I could verify, but they were clear about the role: regional commercialization. That usually means sales access, channel building, distributor relationships, and local market navigation from a hub that already connects well into Southeast Asia’s healthcare system. (manufacturing.economictimes.indiatimes.com) ### Who is doing what? The split is pretty clean. ASMS is taking the commercial side — sales development, channel partnerships, and rollout planning. Huwel is keeping the product side — technology development, manufacturing, regulatory support, and ongoing innovation. That matters because diagnostics expansion usually fails when the science team and the market-entry team are trying to do each other’s jobs. Here, they’re separating them on purpose. (manufacturing.economictimes.indiatimes.com) ### Why Southeast Asia now? Because the region checks a lot of the right boxes at once — rising healthcare spending, more diagnostic awareness, expanding lab infrastructure, and stronger public-health demand. The countries named in the rollout are also large and uneven healthcare markets, which makes a lower(manufacturing.economictimes.indiatimes.com)ve.” (manufacturing.economictimes.indiatimes.com) ### Why is cost the real story? Because Huwel’s platform already has a concrete value argument, not just a branding one. In March, ASMS said it was buying a minority stake in Huwel. At that point, the companies highlighted Quantiplus MTB FAST, a tuberculosis testing platform that had gone through a government-led health technology assessment in India. The number that stands out is cost: about ₹340 per sample, versus roughly ₹700 to ₹1,000 for molecular systems commonly used in government programs. (thehindubusinessline.com) ### Is this only about TB testing? No — but TB is the clearest proof point so far. The Southeast Asia expansion is framed around Quantiplus broadly, and the companies said more products should follow, including portable testing platforms, decentralized molecular systems, rapid screening tools, and specialized diagnostic applications. So the bigger play looks like a regional diagnostics portfolio, with Quantiplus as the first door-opener. (manufacturing.economictimes.indiatimes.com) ### Why is ASMS doing this now? Because this is part of a broader pivot. ASMS — formerly Bartronics India — has been building a healthtech vertical, and its March deal for a minority stake in Huwel set up the commercial relationship before this regional rollout. So this week’s announcement is not a random partnership. It’s the next step in a strategy the company had already started laying down. (thehindubusinessline.com) ### Bottom line? This is a commercialization story disguised as a partnership story. The interesting bit is not that two companies signed a deal — that happens every day. The interesting bit is that they now have a regional route to sell a lower-cost molecular diagnostics platform into six Southeast Asian markets, with Singapore as the hub and cost as the hook. (manufacturing.economictimes.indiatimes.com)